Alliance for Clinical Trials in Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).
Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.
Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.
Top-decile sponsor footprint
Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
446 total, page 2 of 9
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer
NCT03857620
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
NCT03944941
Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making
NCT03766009
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03414970
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
NCT03224767
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
NCT02749903
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
NCT01905046
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT02375204
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
NCT02143726
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT01953588
Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy
NCT01901094
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
NCT01511562
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT00887146
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
NCT00430183
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
NCT00898456
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
NCT00003861
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
NCT00899223
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
NCT00048958
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
NCT04600336
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
NCT03839940
Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma
NCT03870633
Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502
NCT03609021
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
NCT03578081
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT03633331
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT03087708
Pulmonary Rehabilitation Before Lung Cancer Resection
NCT02887521
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
NCT03103321
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
NCT02856581
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
NCT02516423
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
NCT02490878
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
NCT02485834
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
NCT02349412
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
NCT02249949
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT02152137
Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
NCT02229539
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
NCT02116530
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT01805076
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT01838434
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
NCT01573442
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
NCT01644799
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
NCT01781468
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT01814813
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
NCT01821612
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
NCT01556243
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
NCT01429025
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
NCT01497444
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
NCT01334502
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
NCT01414595
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 209 |
| Phase 3 | 142 |
What is open in the Alliance for Clinical Trials in Oncology pipeline
29 recruiting of 446 indexed (7% open); 346 completed (78%).
Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide
Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 446 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- University of Virginia · 449 trials · 22% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 7% open enrollment (± trial volume)
- National Institutes of Health Clinical Center (CC) · 7% recruiting · 338 trials
- Insmed Incorporated · 6% recruiting · 31 trials
- NICHD Neonatal Research Network · 7% recruiting · 61 trials
- Hennepin Healthcare Research Institute · 6% recruiting · 63 trials
Related
What to do with this Alliance for Clinical Trials in Oncology page
446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.
- 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets.Report a data error.